key: cord-0881269-b4mlcyeo authors: Wohlgemuth, N.; Whitt, K.; Cherry, S.; Kirkpatrick Roubidoux, E.; Lin, C.-Y.; Allison, K. J.; Gowen, A.; Freiden, P.; Allen, E. K.; St. Jude Investigative Team,; Gaur, A. H.; Estepp, J. H.; Tang, L.; Mori, T.; Hijano, D. R.; McGargill, M. A.; Krammer, F.; Whitt, M. A.; Wolf, J.; Thomas, P. G.; Schultz-Cherry, S. title: Choosing the right tool for the job: A comprehensive assessment of serological assays for SARS-CoV-2 as surrogates for authentic virus neutralization date: 2021-04-20 journal: nan DOI: 10.1101/2021.04.14.21255399 sha: ab5df8710fa34afa34667d654d45a04cacf80d74 doc_id: 881269 cord_uid: b4mlcyeo Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and has since caused a global pandemic resulting in millions of cases and deaths. Diagnostic tools and serological assays are critical for controlling the outbreak, especially assays designed to quantitate neutralizing antibody levels, considered the best correlate of protection. As vaccines become increasingly available, it is important to identify reliable methods for measuring neutralizing antibody responses that correlate with authentic virus neutralization but can be performed outside of biosafety level 3 (BSL3) laboratories. While many neutralizing assays using pseudotyped virus have been developed, there have been few studies comparing the different assays to each other as surrogates for authentic virus neutralization. Here we characterized three enzyme-linked immunosorbent assays (ELISAs) and three pseudotyped VSV virus neutralization assays and assessed their concordance with authentic virus neutralization. The most accurate assays for predicting authentic virus neutralization were luciferase and secreted embryonic alkaline phosphatase (SEAP) expressing pseudotyped virus neutralizations, followed by GFP expressing pseudotyped virus neutralization, and then the ELISAs. antibody concentration and neutralization activity. Neutralization assays can be performed with 48 authentic virus or a pseudotyped virus expressing the SARS-CoV-2 spike (S) protein on its 49 surface and a marker to measure infection of cells. The clear advantage of a pseudotyped virus 50 is safety, as these studies can be performed in standard BSL2 laboratories. Another advantage 51 is that results using pseudotyped virus can be obtained sooner, typically less than 24 hours 52 whereas with authentic virus, plaque reduction-based neutralization assays take 2-3 days. A 53 third advantage of using pseudotypes is flexibility. Pseudotypes expressing spike variants can 54 be generated easily once the sequence is known since all that is needed is a plasmid that 55 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint 4 expresses the variant of interest. One disadvantage of the pseudotyped virus neutralization 56 assay is the pseudotyped viruses lack all but the spike protein from SARS-CoV-2, meaning they 57 can only be neutralized by spike specific antibodies, and the clustering of proteins may not be 58 representative of authentic virus particles. Yet, few studies have demonstrated whether the 59 neutralization dose 50% (ND50), the dilution at which 50% of virus will be neutralized, differs 60 between pseudotyped virus detection platforms and, importantly, how they compare to authentic (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. pseudotyped virus, suggesting that VSV-ΔG-S-GFP could be a more sensitive assay, it is 106 balanced by increased AUC and ND50 values in negative participants. Only the Luci. and SEAP 107 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint 6 pseudotyped viruses showed no background in samples from PCR-negative participants. A 108 Bland-Altman methods comparison test shows that there is systematic bias between the 109 different pseudotyped virus neutralization assays and the authentic virus neutralization assay, 110 leading to higher variability (highest for GFP pseudotypes) when the signal is low for each assay 111 (Supplemental Figure 1) . However, this bias decreases when signal becomes higher, resulting 112 in the pseudotype assays becoming more concordant with authentic virus neutralization. The (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. While all the serological assays were significantly correlated with authentic virus 153 neutralization, some assays performed better than others at predicting authentic virus 154 neutralization (Supplemental Table 2 ). Based on correlation with authentic virus neutralization, 155 the most accurate assays were the Luci. and SEAP pseudotyped virus neutralization assays. GFP pseudotyped virus neutralization, spike ELISA, and RBD ELISA form a second tier of 157 assays which are still quite accurate at predicting authentic virus neutralization. Furthermore, 158 the GFP pseudotyped virus neutralization was able to detect antibodies at significantly higher 159 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint 8 dilutions than the other assays, making it the most sensitive assay tested. Despite nucleocapsid 160 antigen being the basis for several common commercial antibody tests, nucleocapsid was the 161 least predictive of authentic virus neutralization. Collectively, these data demonstrate that VSV-ΔG pseudotyped virus neutralization 163 platforms, especially Luci. and SEAP based platforms, are better at predicting authentic virus 185 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint In addition to accuracy, the serological assays differ in several key features 186 (Supplemental Table 2 ), and the assay of choice may have to be determined by the settings. The requirement for a BSL3 laboratory makes authentic virus assays technically challenging any of the ELISAs. Overall, this study shows that all six serological assays, to varying degrees, 202 correlated with authentic virus neutralization, and the optimal serological assay for assessing a 203 protective antibody response is going to be institution and question specific. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The O-phenylenediamine dihydrochloride (OPD) substrate was stopped by adding 50 µl of 3M HCl and then the plate was read using a spectrophotometer at 490nm. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint Spike ELISA 332 SARS-CoV-2 spike protein was diluted to a concentration of 2 µg/ml in PBS and added at 50 µl 333 per well to a 96-well ELISA plate. The ELISA plates were sealed and allowed to incubate at 4ºc 334 overnight. The next day the coating solution was removed, and the plates were blocked using 335 3% milk (200 µl per well) for a minimum of 1 hour but not exceeding 4 hours. While the plates 336 were being blocked, the samples were prepared by creating a 3-fold serial dilution starting at 337 1:100 and ending at 1:8100 (1% milk as diluent). Following the blocking period, the milk was 100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mM GlutaMax (Gibco). Media was 356 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint 22 supplemented with 1 mg/mL G418 every other passage. All tissue culture was performed in a 357 humidified incubator set to 37° C and 5% CO2. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint Cherry lab's COVID-19 response; the members of the Thomas, McGargill, and Schultz-Cherry 461 labs for technical assistance and feedback on the work This work was funded by ALSAC, the NIAID 465 for the St. Jude Center of Excellence for Influenza Research and Surveillance (CEIRS contract 466 HHSN27220140006C) and the NIAID Collaborative Influenza Vaccine Innovation Centers Work in the Krammer 469 laboratory is partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers 470 (CIVIC) contract 75N93019C00051 Surveillance (CEIRS, contract # HHSN272201400008C), by the generous support of the Cohen 472 JPB Foundation and the Open Philanthropy Project No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Sample acquisition and curation The authors wish to thank Amy E. Davis, Virginia Hargest, Rebekah Honce, Brandi Livingston, Victoria Meliopoulos, Bridgett Sharp, Maria Smith, and Kristin Wiggins for aiding the Schultz- were returned to the incubator at 37° C and 5% CO2. After 24 h, IU were quantified manually 383 using an EVOS fluorescence microscope. All samples run in duplicate. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint 24 and 5% CO2. After the incubation period, Quanti-Blue (InvivoGen) solution was combined with 409 20 μL supernatant according to manufacturer's instructions and incubated for a minimum of 15 410 minutes at 37° C protected from light. Optical density was measured at 620-655 nm. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255399 doi: medRxiv preprint